8 results found.

Chronic Granulomatous Disease, Healthy, Immunologic Disease, Leuk Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 65 years.
- Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells.

Chronic Granulomatous Disease (CGD), Atherosclerosis, Immune Defi Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System.

Chronic Granulomatous Disease Clinical Trial using Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells

National Institutes of Health Clinical Center (CC) - Recruiting 3 years to 55 years.
- Autologous Transplantation of Genetically Modified Cells for the Treatment of X-Linked Chronic Granulomatous Disease.
Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells

IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, Chron Clinical Trial using IFN-gamma

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Assessment of the Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease.
IFN-gamma

Radiofrequency Ablation, Liver Abscesses -Staphylococcus Infectio Clinical Trial using RFA - Radiofrequency Ablation; Scans - Liver; Liver; Drawn

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Radiofrequency Ablation (RFA) for the Treatment of Liver Abscesses in Patients With Chronic Granulomatous Disease.
RFA - Radiofrequency Ablation; Scans - Liver; Liver; Drawn

Immune Disorders, Chronic Granulomatous Disease, Genetic Immunolo Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility.

Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskot Clinical Trial using 4 doses of abatacept; 6 doses of abatacept

Emory University - Recruiting N/A to 21 years.
- Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Disease: a Dose Assessment Pilot.
4 doses of abatacept; 6 doses of abatacept

Severe Combined Immunodeficiency (SCID), Immunodeficiency With Pr Clinical Trial using CD3/CD19 negative allogeneic hematopoietic stem cells

University of Pittsburgh - Recruiting 5 years to 40 years.
- Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors.
CD3/CD19 negative allogeneic hematopoietic stem cells